Written and maintained by CASRAI Editorial Board
Published · Last updated
This page describes products and general use; it is not medical advice.
On this page
Short answer
Tegaderm CHG is an integrated antimicrobial vascular access dressing combining a breathable transparent film with an absorbent 2% chlorhexidine gluconate (CHG) gel pad. Cleared under FDA 510(k) K171908, it secures catheters, maintains insertion site visibility, and provides antimicrobial activity to reduce catheter-related bloodstream infections (CRBSIs) during clinical care and trial protocols.
Definition and scope
Tegaderm CHG (manufactured by 3M / Solventum) is an antimicrobial securement device engineered to protect vascular access sites while stabilizing indwelling catheters. Unlike standard transparent film dressings that act only as passive barriers, Tegaderm CHG integrates an antiseptic agent directly into its wound contact layer.
In United States regulatory classification, the Food and Drug Administration (FDA) catalogs the device as an unclassified medical device under product codes FRO (“Dressing, wound, drug”) and SEL (“Securement Wound Dressing For Reduction Of Infection”). Clearance was granted via 510(k) premarket notification K171908. Cleared indications include covering and protecting catheter sites, securing percutaneous devices to skin, and reducing vascular catheter colonization and catheter-related bloodstream infections (CRBSIs) in patients with central venous or arterial lines.
In healthcare supply management, Tegaderm CHG forms a distinct tier from the standard Tegaderm IV dressing line. Non-antimicrobial film dressings rely solely on border notches and film adhesion. In contrast, the CHG line incorporates calibrated quantities of chlorhexidine gluconate (15 mg to 78 mg across catalog sizes such as 1657, 1658, 1659, and 1660) to suppress skin flora without requiring a separate antiseptic disk.
How it works or how it is used in practice
Tegaderm CHG combines a 2% weight-by-weight (w/w) chlorhexidine gluconate hydrophilic gel pad with a semipermeable polyurethane backing. Upon skin contact, the gel absorbs cutaneous moisture while continuously releasing chlorhexidine around the puncture tract. In vitro testing documented in FDA 510(k) reviews demonstrates antimicrobial and antifungal activity against gram-positive and gram-negative bacteria, and yeasts, suppressing microbial regrowth beneath the dressing.
The overlying polyurethane film acts as a waterproof barrier against environmental contaminants and viruses (tested effective against viral particles 27 nm or larger while intact). Concurrently, moisture vapor transmission prevents peri-catheter skin maceration while maintaining optical transparency so clinicians can inspect for erythema or discharge without disturbing the dressing seal.
In clinical practice, manufacturer documentation indicates a wear time of up to 7 days, aligning with weekly catheter maintenance intervals. Clinicians monitor pad saturation during routine inspections: if the gel pad becomes fully saturated with fluid or blood, loses translucency, or fails an elasticity check, dressing replacement is required.
Types or related concepts
Vascular site protection uses several distinct dressing strategies. Comparing integrated antiseptic films, multi-component sponge systems, and plain polymer films helps supply managers and trial monitors evaluate infection control options.
| Dressing Concept | Antimicrobial Component | Site Visibility | Moisture Management | Sourced Clinical Application |
|---|---|---|---|---|
| Integrated CHG Gel Dressing (3M Tegaderm CHG) | Bonded 2% w/w chlorhexidine gluconate hydrophilic gel pad | Continuous transparency through film and gel pad | Gel pad absorbs exudate; breathable film backing | Short-term CVCs, PICCs, and arterial lines in acute care, ICUs, and clinical trials |
| Separate CHG Foam Disk + Film (e.g., Biopatch protective disk with standard film) | Polyurethane foam sponge impregnated with chlorhexidine gluconate | Opaque foam disk conceals immediate skin puncture site | Foam sponge wicks fluid locally; requires separate adhesive cover film | Catheter bundles utilizing modular components rather than integrated dressings |
| Standard Transparent Film (e.g., standard transparent IV dressing) | None (mechanical barrier only; non-medicated) | Full optical transparency across entire dressing | Semipermeable moisture vapor exchange without active antimicrobial release | Low-risk peripheral IV lines or non-infected vascular access where antiseptic release is unneeded |
Where it matters for labs, clinics or supply decisions
Formulary inclusion of Tegaderm CHG is guided by infection prevention guidelines, clinical evidence, and reimbursement coding schedules.
Central line-associated bloodstream infections (CLABSIs) cause substantial patient morbidity and hospital cost. Including chlorhexidine dressings in an institutional CLABSI prevention bundle provides an automated antiseptic barrier at the insertion site. The Centers for Disease Control and Prevention (CDC) Guidelines for the Prevention of Intravascular Catheter-Related Infections issue a Category IA recommendation for using chlorhexidine-impregnated dressings with FDA-cleared CRBSI-reduction indications on short-term, non-tunneled central venous catheter sites in adult patients aged 18 and older.
Health technology assessments also support adoption. The UK National Institute for Health and Care Excellence (NICE), under Medical Technologies Guidance MTG25 / HTG379, concluded that Tegaderm CHG dressings reduce catheter-related bloodstream infections compared to non-medicated dressings. NICE economic modeling estimated a net NHS cost-saving of approximately £93 per patient in intensive care units by preventing costly bloodstream infections.
For outpatient supply procurement and billing, Tegaderm CHG maps to specific Healthcare Common Procedure Coding System (HCPCS) codes. When dispensed for outpatient infusion catheter maintenance, it is crosswalked to code A4221 (supplies for maintenance of non-insulin drug infusion catheter, per week). Under surgical and wound dressing fee schedules based on surface area, sterile transparent film dressings map to codes A6257 (16 sq in or less), A6258 (more than 16 to 48 sq in), or A6259 (greater than 48 sq in).
Common misunderstandings
Supply evaluations and audits highlight several common misconceptions:
- Confusing Tegaderm CHG with standard Tegaderm film. Standard films provide mechanical barrier protection only. Tegaderm CHG is an unclassified drug-device combination (codes FRO and SEL) containing an active 2% chlorhexidine gluconate gel pad.
- Assuming the dressing treats active bacteremia. The FDA-cleared indication is prophylactic: reducing catheter colonization and CRBSI risk. It does not treat established systemic bloodstream infections.
- Use in premature neonates or infants under 2 months. Tegaderm CHG is contraindicated in premature infants and neonates under 2 months of age. Immature skin barrier function creates risk for chemical burns, severe dermatitis, and necrosis (classified by CDC as Category IC).
- Exceeding 7-day wear intervals. While dressings may appear intact, antimicrobial release and adhesion are validated up to 7 days. Exceeding recommended intervals increases edge lift and contamination risk.
- Vertical dressing removal. Pulling transparent dressings straight upward causes mechanical skin trauma and risks catheter dislodgement. Instructions specify a “low and slow” horizontal peel back along the skin, loosening the gel pad with sterile saline or alcohol if adherent.
Frequently asked questions
What is the difference between Tegaderm and Tegaderm CHG?
Standard Tegaderm consists of a transparent adhesive polyurethane film that shields insertion sites from external contamination without delivering antiseptic agents. Tegaderm CHG incorporates an absorbent 2% chlorhexidine gluconate gel pad beneath the film, providing continuous antimicrobial suppression against skin microflora around the catheter entry point.
How long can a Tegaderm CHG dressing remain in place?
Tegaderm CHG is cleared for up to 7 days of continuous wear on intact skin, matching routine weekly catheter line change protocols. The dressing should be replaced sooner if the border lifts, if it becomes soiled or loose, or if the gel pad becomes fully saturated with fluid.
Why is Tegaderm CHG contraindicated in premature infants?
The dressing is contraindicated in premature infants and neonates under 2 months of age because fragile newborn skin is vulnerable to chemical burns, severe contact irritation, and skin necrosis from chlorhexidine gluconate, along with risk of systemic absorption.
What HCPCS billing codes apply to Tegaderm CHG dressings?
In outpatient infusion catheter maintenance, Tegaderm CHG dressings are commonly billed under HCPCS code A4221 (catheter maintenance supplies, per week). Under wound dressing schedules based on surface area, transparent film dressings are billed under A6257 (16 sq in or less), A6258 (more than 16 to 48 sq in), or A6259 (more than 48 sq in).
Sources
- U.S. Food and Drug Administration (FDA). 510(k) Premarket Notification K171908: 3M Tegaderm CHG Chlorhexidine Gluconate I.V. Securement Dressing. Cleared July 11, 2017. https://www.accessdata.fda.gov/cdrh_docs/pdf17/K171908.pdf (read 2026-11-09).
- Centers for Disease Control and Prevention (CDC). Guidelines for the Prevention of Intravascular Catheter-Related Infections (2011 and 2017 Focused Update). https://www.cdc.gov/infectioncontrol/guidelines/bsi/ (read 2026-11-09).
- National Institute for Health and Care Excellence (NICE). Medical Technologies Guidance MTG25 / HTG379: 3M Tegaderm CHG IV Securement Dressing. https://www.nice.org.uk/guidance/mtg25 (read 2026-11-09).
- 3M / Solventum. Tegaderm CHG Chlorhexidine Gluconate I.V. Securement Dressing Instructions for Use and Technical Specifications. https://www.solventum.com (read 2026-11-09).
- Centers for Medicare and Medicaid Services (CMS). Healthcare Common Procedure Coding System (HCPCS) Coding Decisions and Quarterly Updates. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system (read 2026-11-09).
